专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2020106560A1 SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE 审中-公开
公开(公告)号：WO2020106560A1
公开(公告)日：2020-05-28
申请号：PCT/US2019/061634
申请日：2019-11-15
申请人： MERCK SHARP & DOHME CORP. , BRILL, Zachary, G. , ALI, Amjad , CUMMING, Jared , DEMONG, Duane , DENG, Qiaolin , GALLO-ETIENNE, Gioconda, V. , GRAHAM, Thomas, H. , KUANG, Rongze , LARSEN, Matthew, A. , LIM, Yeon-Hee , LIU, Kun , MANSOOR, Umar Faruk , MORENO, Jesus , VARA, Brandon, A. , WANG, Huijun , ZHANG, Yonglian
发明人： BRILL, Zachary, G. , ALI, Amjad , CUMMING, Jared , DEMONG, Duane , DENG, Qiaolin , GALLO-ETIENNE, Gioconda, V. , GRAHAM, Thomas, H. , KUANG, Rongze , LARSEN, Matthew, A. , LIM, Yeon-Hee , LIU, Kun , MANSOOR, Umar Faruk , MORENO, Jesus , VARA, Brandon, A. , WANG, Huijun , ZHANG, Yonglian
IPC分类号： A61K31/519 , A61K31/4985 , C07D487/04
摘要： In its many embodiments, the present invention provides certain substituted amino triazolopyrimidine and amino triazolopyrazine compounds of Formula (IA) and Formula (IB): and, and pharmaceutically acceptable salts thereof, wherein, R 1 , n, R 2 , and R 3 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

2. 发明申请

WO2020106558A1 SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE 审中-公开
公开(公告)号：WO2020106558A1
公开(公告)日：2020-05-28
申请号：PCT/US2019/061622
申请日：2019-11-15
申请人： MERCK SHARP & DOHME CORP. , BRILL, Zachary, G. , ALI, Amjad , CUMMING, Jared , DEMONG, Duane , DENG, Qiaolin , GRAHAM, Thomas, H. , KUANG, Rongze , LIM, Yeon-Hee , PLUMMER, Christopher, W. , RICO DUQUE, Jenny Lorena , WANG, Huijun , ZHANG, Yonglian , ZHAO, Kake
发明人： BRILL, Zachary, G. , ALI, Amjad , CUMMING, Jared , DEMONG, Duane , DENG, Qiaolin , GRAHAM, Thomas, H. , KUANG, Rongze , LIM, Yeon-Hee , PLUMMER, Christopher, W. , RICO DUQUE, Jenny Lorena , WANG, Huijun , ZHANG, Yonglian , ZHAO, Kake
IPC分类号： A61K31/519 , A61P35/00 , C07D487/04
摘要： In its many embodiments, the present invention provides certain substituted amino triazolopyrimidine and amino triazolopyrazine compounds of Formula (IA) and Formula (IB): or and pharmaceutically acceptable salts thereof, wherein, R 1 , R 2 , and R 3 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

3. 发明申请

WO2020112700A1 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE 审中-公开
公开(公告)号：WO2020112700A1
公开(公告)日：2020-06-04
申请号：PCT/US2019/063136
申请日：2019-11-26
申请人： MERCK SHARP & DOHME CORP. , LARSEN, Matthew, A. , ALI, Amjad , CUMMING, Jared , DEMONG, Duane , DENG, Qiaolin , GRAHAM, Thomas, H. , HENNESSY, Elisabeth , HOOVER, Andrew, J. , LIU, Ping , LIU, Kun , MANSOOR, Umar Faruk , PAN, Jianping , PLUMMER, Christopher, W. , SATHER, Aaron , SWAMINATHAN, Uma , WANG, Huijun , ZHANG, Yonglian
发明人： LARSEN, Matthew, A. , ALI, Amjad , CUMMING, Jared , DEMONG, Duane , DENG, Qiaolin , GRAHAM, Thomas, H. , HENNESSY, Elisabeth , HOOVER, Andrew, J. , LIU, Ping , LIU, Kun , MANSOOR, Umar Faruk , PAN, Jianping , PLUMMER, Christopher, W. , SATHER, Aaron , SWAMINATHAN, Uma , WANG, Huijun , ZHANG, Yonglian
IPC分类号： A61P35/00 , C07D487/04 , A61K31/519
摘要： In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): (I), and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

4. 发明申请

WO2020112706A1 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE 审中-公开
公开(公告)号：WO2020112706A1
公开(公告)日：2020-06-04
申请号：PCT/US2019/063146
申请日：2019-11-26
申请人： MERCK SHARP & DOHME CORP. , ZHANG, Yonglian , ALI, Amjad , CUMMING, Jared , DEMONG, Duane , DENG, Qiaolin , GRAHAM, Thomas, H. , HENNESSY, Elisabeth , LARSEN, Matthew, A. , LIU, Kun , LIU, Ping , MANSOOR, Umar Faruk , PAN, Jianping , PLUMMER, Christopher, W. , SATHER, Aaron , SWAMINATHAN, Uma , WANG, Huijun
发明人： ZHANG, Yonglian , ALI, Amjad , CUMMING, Jared , DEMONG, Duane , DENG, Qiaolin , GRAHAM, Thomas, H. , HENNESSY, Elisabeth , LARSEN, Matthew, A. , LIU, Kun , LIU, Ping , MANSOOR, Umar Faruk , PAN, Jianping , PLUMMER, Christopher, W. , SATHER, Aaron , SWAMINATHAN, Uma , WANG, Huijun
IPC分类号： C07D487/04 , C07D487/08 , C07D487/18
摘要： In its many embodiments, the present invention provides certain 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives of Formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R2, and R4 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutic agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

9. 发明申请

WO2010137766A1 HYBRID POLE BEARINGLESS SRM 审中-公开
标题翻译：混合式无轴承SRM
公开(公告)号：WO2010137766A1
公开(公告)日：2010-12-02
申请号：PCT/KR2009/003844
申请日：2009-07-14
申请人： KYUNGSUNG UNIVERSITY INDUSTRY COOPERATION FOUNDATION , AHN, Jinwoo , LEE, Donghee , WANG, Huijun
发明人： AHN, Jinwoo , LEE, Donghee , WANG, Huijun
IPC分类号： H02K37/02
CPC分类号： H02K7/09 , H02K19/103
摘要： Disclosed is a hybrid pole bearingless switched reluctance motor (BLSRM). The BLSRM includes a stator provided with windings, a rotor rotating about an axis when current is conducted to the windings. The rotor includes a plurality of rotor poles extending radially outward, and the stator includes a plurality of stator poles extending radially inward. The windings include suspending windings to generate radial force for the rotor and torque windings to generate torque. The suspending windings are mutually separated from the torque windings. Through the use of the hybrid pole BLSRM, a stator pole generating the radial force can be controlled independently from the stator pole generating the torque by separately arranging the stator pole generating the radial force and the stator pole generating torque based on the analysis of radial force and torque characteristics according to the position of the stator poles.
摘要翻译：公开了一种混合无极轴承开关磁阻电动机（BLSRM）。 BLSRM包括具有绕组的定子，当电流传导到绕组时围绕轴旋转的转子。转子包括径向向外延伸的多个转子极，并且定子包括径向向内延伸的多个定子极。绕组包括悬挂绕组以产生用于转子和扭矩绕组产生转矩的径向力。悬挂绕组与转矩绕组相互分离。通过使用混合极BLSRM，可以独立于定子极控制产生径向力的定子极，通过分别布置产生径向力的定子极和基于径向力分析的定子极产生转矩来产生转矩并根据定子极的位置进行转矩特性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式